In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B
about
sameAs
Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instabilityInhibition of centromere dynamics by eribulin (E7389) during mitotic metaphasePatient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice GuideCapturing Biological Activity in Natural Product Fragments by Chemical SynthesisEribulin in the Management of Advanced Breast Cancer: Implications of Current Research FindingsEribulin in Cancer TreatmentCancer across the tree of life: cooperation and cheating in multicellularityA novel microtubule inhibitor 4SC-207 with anti-proliferative activity in taxane-resistant cellsEribulin in the management of inoperable soft-tissue sarcoma: patient selection and survivalEfficacy and safety of eribulin mesylate in advanced soft tissue sarcomasEribulin for the treatment of metastatic breast cancer: an update on its safety and efficacyGene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cellsA novel natural phenyl alkene with cytotoxic activityNature's bounty - drug discovery from the seaWhat lies underneath: conserving the oceans' genetic resourcesEfficacy of eribulin in breast cancer: a short report on the emerging new data.Functionally Optimized Neuritogenic Farinosone C Analogs: SAR-Study and Investigations on Their Mode of ActionNovel microtubule-targeted agent 6-chloro-4-(methoxyphenyl) coumarin induces G2-M arrest and apoptosis in HeLa cells.Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.Exploratory research on bioactive natural products with a focus on biological phenomena.Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) statesEribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer modelsSingle-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin.Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells.Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine AInitial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing programPhase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.ELR510444, a novel microtubule disruptor with multiple mechanisms of actionPhase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.Interactions of halichondrin B and eribulin with tubulin.Marketed marine natural products in the pharmaceutical and cosmeceutical industries: tips for successCellular studies reveal mechanistic differences between taccalonolide A and paclitaxel.Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer.Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.Eribulin mesylate in the treatment of metastatic breast cancerPhase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxaneOridonin-induced apoptosis in SW620 human colorectal adenocarcinoma cells.Eribulin mesylate in patients with refractory cancers: a Phase I study.Chemical Diversity of Metabolites from Fungi, Cyanobacteria, and Plants Relative to FDA-Approved Anticancer Agents.
P2860
Q24610709-0D8FC4DF-5100-4BA8-9CC9-914140821B75Q24657514-CBA96904-E085-4776-BC0B-69C0E9F5BE85Q26749476-F0B8F01F-E45C-4BAC-BFBA-1E04697709CFQ26772873-07232D09-91C2-4CDE-8D1E-30AB569E6962Q26774097-F6FB6063-BABE-41F1-ADBA-014CC8190DA4Q26799328-4D433003-8037-413C-A411-E1E639B90450Q27026902-D0A8E89E-CECD-43C7-8323-2E766AD29D2FQ27302772-D5E99469-9497-406A-8499-B2AEF854E1BFQ28074125-E30B559B-7532-418D-A2AB-C5C6BD41B066Q28078116-0EA0EBB2-3ABD-4AD3-8E41-E9B7E357D5EAQ28088354-A13BDA23-9378-40C3-A84C-89471A8EC568Q28542669-DACB48BE-3B6D-4FBB-868A-40E10B84B6B5Q28820748-49E97B2D-C14A-45EA-9351-DAF10EB47E3EQ28828257-466CBA15-4FE9-4F99-B944-56FFC7EB66E4Q30396299-EEA404D2-AA63-4EFE-B68A-B265A7CD76D4Q31167441-7C00763F-47FA-4934-92CD-95A2CE4565B6Q33636160-EF64A80F-769E-456E-BA58-C5BD9CB772ABQ33828711-1479E2D9-D025-4D8E-9ECC-426045641948Q33941497-6A9BC67A-9FE5-46E6-A82F-CC08D4C2F5D9Q34062522-E85A6354-2A87-4652-9D57-96B32D86A259Q34103874-025A49CD-C15C-4101-9DA8-8FEA17288DB6Q34406761-8935880B-3787-4A6E-AADA-8813B2D031D3Q34430739-FD430A39-CD8A-40D7-9847-DFD4698BD302Q34446806-A8943747-3570-4C2A-BF7C-EC14AF4062C5Q34466428-209FCCEC-140F-4CB6-9416-B3A1BFA033C3Q34520772-7CBFD1D3-ACA9-4A64-8FD8-EF4932532395Q34683835-022F086F-B2F6-458A-8A03-FE49CC2FBD5AQ34687059-843A42EB-55D7-49FC-8196-E8D3DD092ED6Q34702388-152387C4-CDD4-46E8-B70E-B61675CC938EQ34964991-5A8F8D8E-7275-4E79-B186-9CE82A9B90B5Q35088820-437AA5C1-DDC0-4573-9C02-65B39E5C790AQ35096907-43DD8CD6-10A6-4AE0-BCD0-7B317C12B64CQ35158843-945B76CC-6EF5-4F4F-B0FD-9AC0FDE2C122Q35599745-93E8B368-5247-40EE-AEFE-B95ACE3BDC2AQ35633159-B0F68C48-46EB-4E34-A16E-EEAF0954D7FBQ35699382-35498B6A-3319-4BE7-A81D-D0B1553173F2Q35721526-00EA91F4-8047-4B43-AABA-86888FFB4CBEQ36121430-AE0ABB54-C371-4859-8904-E1F09646D70BQ36205403-9697370F-B6DB-4FC2-A8BD-C47561B52707Q36237762-B5339C28-3C2F-41C3-BED7-3C12E6710126
P2860
In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B
description
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2001
@ast
im Februar 2001 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: February 2001)
@en
vedecký článok (publikovaný 2001/02/01)
@sk
vědecký článek publikovaný v roce 2001
@cs
wetenschappelijk artikel (gepubliceerd op 2001/02/01)
@nl
наукова стаття, опублікована в лютому 2001
@uk
مقالة علمية (نشرت في فبراير 2001)
@ar
name
In vitro and in vivo anticance ...... ne analogues of halichondrin B
@ast
In vitro and in vivo anticance ...... ne analogues of halichondrin B
@en
In vitro and in vivo anticance ...... ne analogues of halichondrin B
@nl
type
label
In vitro and in vivo anticance ...... ne analogues of halichondrin B
@ast
In vitro and in vivo anticance ...... ne analogues of halichondrin B
@en
In vitro and in vivo anticance ...... ne analogues of halichondrin B
@nl
prefLabel
In vitro and in vivo anticance ...... ne analogues of halichondrin B
@ast
In vitro and in vivo anticance ...... ne analogues of halichondrin B
@en
In vitro and in vivo anticance ...... ne analogues of halichondrin B
@nl
P2093
P3181
P1433
P1476
In vitro and in vivo anticance ...... ne analogues of halichondrin B
@en
P2093
B A Littlefield
B M Seletsky
D A Quincy
G J Habgood
G Kuznetsov
K A Salvato
P304
P3181
P407
P577
2001-02-01T00:00:00Z